Minimizing liability risks under the ACMG recommendations for reporting incidental findings in clinical exome and genome sequencing.
about
Genomic sequencing: assessing the health care system, policy, and big-data implications.Can I be sued for that? Liability risk and the disclosure of clinically significant genetic research findingsReturn of results: ethical and legal distinctions between research and clinical care.Return of genomic results to research participants: the floor, the ceiling, and the choices in between.Clinical Sequencing Exploratory Research Consortium: Accelerating Evidence-Based Practice of Genomic Medicine.The First Amendment Right to Speak About the Human Genome.Diagnostics of primary immunodeficiency diseases: a sequencing capture approachLiving laboratory: whole-genome sequencing as a learning healthcare enterprise.The fiduciary relationship model for managing clinical genomic "incidental" findings.The cost-effectiveness of returning incidental findings from next-generation genomic sequencing.Research participants in NGS studies want to know about incidental findingsDiagnostic use of Massively Parallel Sequencing in Neuromuscular Diseases: Towards an Integrated Diagnosis.Towards precision nephrology: the opportunities and challenges of genomic medicine.Incidental or secondary findings: an integrative and patient-inclusive approach to the current debateOpportunities and Challenges for Genetic Studies of End-Stage Renal Disease in Canada
P2860
Q30835712-5D685D97-23FF-477D-85FF-4837B2CE4321Q33564494-779B7BB2-4A9C-416A-8D34-12F714DA1A3FQ33835535-C84F4142-4647-4C63-8564-0DC0A2981F2BQ34000877-534B172B-66DE-414E-A3EC-366AB644A251Q34526631-6744ADD3-9C86-4437-B3AC-3E2CE8395640Q34598587-FE972B04-F9A5-46B9-A5C1-29088D3A7F26Q34681895-23E7F364-9D0B-4833-B76A-9540044D235AQ34995956-1A695A07-F712-4243-8783-77F74AFECD62Q35034175-0B2935DB-E40C-4758-88ED-19A58CF5176CQ35602902-23FCC428-63F4-42E1-94B3-EA02DFBF22A2Q36116704-053F7C5C-6014-421C-98C6-1DE5B58C30A1Q37589634-B9181136-7743-4CEE-A838-56F1A93EADBDQ48171722-6597A998-2D49-4412-97B0-6EC53960D7B5Q56527776-0006EA64-D5A9-4407-8DB4-F5BF9291FB94Q57175118-311432C2-AEA0-4FF8-9356-5B52E61B7E0D
P2860
Minimizing liability risks under the ACMG recommendations for reporting incidental findings in clinical exome and genome sequencing.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 12 September 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Minimizing liability risks und ...... l exome and genome sequencing.
@en
Minimizing liability risks und ...... l exome and genome sequencing.
@nl
type
label
Minimizing liability risks und ...... l exome and genome sequencing.
@en
Minimizing liability risks und ...... l exome and genome sequencing.
@nl
prefLabel
Minimizing liability risks und ...... l exome and genome sequencing.
@en
Minimizing liability risks und ...... l exome and genome sequencing.
@nl
P2860
P356
P1433
P1476
Minimizing liability risks und ...... l exome and genome sequencing.
@en
P2093
Barbara J Evans
P2860
P2888
P304
P356
10.1038/GIM.2013.135
P407
P577
2013-09-12T00:00:00Z